00950.HK
Lee's Pharmaceutical Holdings Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 1.21
+6.61%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.9B | 1.4B | 1.4B | 1.1B | 1.2B |
| Cost of Revenue | 895.3M | 706.4M | 646.6M | 501.7M | 462.4M |
| Gross Profit | 1.0B | 729.6M | 753.4M | 551.3M | 770.8M |
| Operating Expenses | |||||
| R&D Expense | 356.3M | 169.0M | 83.8M | 96.8M | 168.9M |
| SG&A Expense | 670.4M | 557.1M | 596.3M | 494.2M | 544.9M |
| General & Admin Expense | 307.5M | 223.0M | 195.3M | 188.6M | 198.4M |
| Selling & Marketing Expense | 361.9M | 334.0M | 387.3M | 304.3M | 346.5M |
| Other Expenses | 21.8M | (82.5M) | (39.9M) | (83.2M) | (19.3M) |
| Total Operating Expenses | 1.0B | 643.6M | 640.2M | 507.8M | 694.5M |
| Cost and Expenses | 1.9B | 1.4B | 1.3B | 1.0B | 1.2B |
| Operating Income (EBIT) | (7.8M) | 86.0M | 113.1M | 43.6M | 76.6M |
| Non-Operating | |||||
| Interest Income | 1.7M | 1.8M | 1.8M | 1.5M | 2.4M |
| Interest Expense | 10.6M | 11.2M | 13.8M | 11.9M | 7.6M |
| Net Interest Income | (9.2M) | (9.4M) | (12.1M) | (10.4M) | (5.2M) |
| Other Non-Op Income/Expense | 149.7M | (13.1M) | (15.0M) | (12.8M) | (8.7M) |
| Non-Operating Income (excl Interest) | (21.0M) | (24.3M) | 1.2M | 7.5M | 2.0M |
| EBT (Pre-Tax Income) | 141.9M | 72.9M | 98.1M | 30.8M | 67.9M |
| Income Tax Expense | 47.5M | 22.3M | 29.5M | 10.8M | 22.0M |
| Bottom Line | |||||
| Net Income | 167.3M | 91.9M | 93.1M | 16.7M | 51.3M |
| Earnings from Cont. Ops | 94.4M | 50.6M | 68.6M | 19.9M | 45.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 167.3M | 91.9M | 93.1M | 16.7M | 51.3M |
| Per Share | |||||
| Basic EPS | HK$0.28 | HK$0.16 | HK$0.16 | HK$0.03 | HK$0.09 |
| Diluted EPS | HK$0.28 | HK$0.16 | HK$0.16 | HK$0.03 | HK$0.09 |
| Revenue Per Share | HK$3.29 | HK$2.44 | HK$2.38 | HK$1.79 | HK$2.09 |
| Shares | |||||
| Basic Shares Outstanding | 588.8M | 589.0M | 588.8M | 588.8M | 588.8M |
| Diluted Shares Outstanding | 589.0M | 589.0M | 588.8M | 588.8M | 588.8M |
| Profitability Metrics | |||||
| EBITDA | 173.8M | 198.0M | 260.9M | 193.1M | 229.1M |
| D&A | 160.6M | 87.8M | 147.7M | 149.5M | 152.5M |
| EBIT | 13.3M | 110.3M | 111.9M | 43.6M | 76.6M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026